Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection

Benzer Materyaller

• Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
  Yazar:: Latinovic, Olga, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
  Yazar:: Giaquinto, Carlo, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
  Yazar:: Abel, Samantha, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir
  Yazar:: Westby, Mike, ve diğerleri
  Baskı/Yayın Bilgisi: (2006)
• Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
  Yazar:: Lorenzen, Thore
  Baskı/Yayın Bilgisi: (2010)